Immunomic Teams Up With PharmaJet and EpiVax on COVID-19 Vaccine

Immunomic Therapeutics has entered into a collaboration with PharmaJet and EpiVax to develop a nucleic acid vaccine candidate against COVID-19.

The partners aim to create a vaccine that is scalable, heat-stable and easy to administer using PharmaJet’s Tropis needle-free injection system. 

Immunomic’s UNITE platform has previously been used to create vaccine candidates for numerous diseases, including Severe Acute Respiratory Syndrome (SARS), which is caused by a virus related to the SARS-Cov-2 coronavirus.